Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription 08.09.2025 1 AJR Am J Roentgenol 5 Am J Gastroenterol 1 Ann Intern Med 1 Biochem Biophys Res Commun 3 BMC Cancer 2 BMC Gastroenterol 2 Cancer Res 4 Dig Dis Sci 1 Endoscopy 1 Eur Radiol 1 Gut 6 Hepatology 2 Int J Cancer 4 J Gastroenterol Hepatol 4 J Hepatol 1 J Pediatr Surg 2 Oncogene 1 PLoS Comput Biol 2 PLoS One 2 Radiol Imaging Cancer 2 Transplant Proc

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. CASTAGNOLI F
   Turning Anatomy Into Action: Everything You Wanted to Know About Hepatocellular Carcinoma-and Need to Know for Your Next Report.
   AJR Am J Roentgenol. 2025 Sep 3. doi: 10.2214/AJR.25.33791.
   PubMed        
   
   

   
   Am J Gastroenterol

2. SINGAL AK, Pannerselvam D, Arab JP, Im G, et al
   Delisting From Liver Transplant List for Improvement and Re-compensation Among Decompensated Patients at one-year.
   Am J Gastroenterol. 2024 Dec 23. doi: 10.14309/ajg.0000000000003259.
   PubMed         Abstract available
   
   
3. MAHMUD N, Fricker ZP, McElroy LM, Qayed E, et al
   ACG Clinical Guideline: Perioperative Risk Assessment and Management in Patients With Cirrhosis.
   Am J Gastroenterol. 2025;120:1968-1984.
   PubMed         Abstract available
   
   
4. NIU C, Sun K, Zhang J, Elkhapery A, et al
   Gastrointestinal and Hepatobiliary Safety of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
   Am J Gastroenterol. 2025 Sep 3. doi: 10.14309/ajg.0000000000003760.
   PubMed         Abstract available
   
   
5. MALIK S, Frey LJ, Gutman J, Mushtaq A, et al
   Evaluating Artificial Intelligence-Driven Responses to Acute Liver Failure Queries: A Comparative Analysis Across Accuracy, Clarity, and Relevance.
   Am J Gastroenterol. 2024;120:2081-2085.
   PubMed         Abstract available
   
   
6. SERPER M, Pulaski ME, Zhang S, Taddei TH, et al
   Albumin for Spontaneous Bacterial Peritonitis: Care Variation, Disparities, and Outcomes.
   Am J Gastroenterol. 2024;120:2059-2071.
   PubMed         Abstract available
   
   

   
   Ann Intern Med

7. IMPERIALE TF
   In MASH with moderate or advanced liver fibrosis, weekly semaglutide improved histologic steatohepatitis and fibrosis at 72 wk.
   Ann Intern Med. 2025 Sep 2. doi: 10.7326/ANNALS-25-03308.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

8. ZHANG K, Gan Y, Chen Y, Jiang Z, et al
   A multi-biomarker panel for non-invasive diagnosis, risk stratification, subtype identification, and therapeutic targeting in NAFLD: bioinformatics and experimental insights.
   Biochem Biophys Res Commun. 2025;779:152403.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. MCMILLAN MT, Reyngold M, Crane CH, O'Brien DAR, et al
   A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC).
   BMC Cancer. 2025;25:1408.
   PubMed         Abstract available
   
   
10. GAO X, Hao W, Wang Y, Wu X, et al
    Molecular mechanisms of astragaloside-IV in hepatocellular carcinoma therapy: a systematic review.
    BMC Cancer. 2025;25:1407.
    PubMed         Abstract available
    
    
11. LI Y, Liu YM, Gao YL, Xiao ZQ, et al
    Comparison of the accuracy of predictive models in early detection of clinically relevant posthepatectomy liver failure.
    BMC Cancer. 2025;25:1400.
    PubMed         Abstract available
    
    

    
    BMC Gastroenterol

12. MOHAMMED YMH, Abdelgader AAM, Ahmed IB, Zidan YM, et al
    Clinical and endoscopic findings of patients presenting with upper gastrointestinal bleeding in Khartoum, Sudan: a cross-sectional study.
    BMC Gastroenterol. 2025;25:636.
    PubMed         Abstract available
    
    
13. GUO H, Yin N, Liu J, Li A, et al
    Acute versus acute-on-chronic liver failure: comparative analysis of clinical outcomes in Beijing, China.
    BMC Gastroenterol. 2025;25:637.
    PubMed         Abstract available
    
    

    
    Cancer Res

14. WU YD, Huang XX, Zhang HX, Pan Y, et al
    TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis.
    Cancer Res. 2025;85:3292-3312.
    PubMed         Abstract available
    
    
15. FU C, Fu W, Huang Z, He X, et al
    Long-Chain Fatty Acid Redistribution Induced by SLC27A2 Deficiency Facilitates Hypoxic Adaptation and Immunosuppression in Hepatocellular Carcinoma.
    Cancer Res. 2025 Sep 3. doi: 10.1158/0008-5472.CAN-25-1693.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

16. ILAGAN-YING YC
    An AUDacious Proposal: How to Improve Gastroenterology Fellow Training for Alcohol Use Disorder and Alcohol-Associated Liver Disease.
    Dig Dis Sci. 2025;70:2940-2943.
    PubMed         Abstract available
    
    
17. NIU J, Wu W, Zhang H, Li Z, et al
    Correction: Aflatoxin B1 Promotes M2-like Macrophage Polarization via IL-6 Expression in Hepatocellular Carcinoma.
    Dig Dis Sci. 2025 Sep 4. doi: 10.1007/s10620-025-09376.
    PubMed        
    
    
18. JINDAL A, Singh H, Sharma MK, Vashistha C, et al
    Correlation of Spleen Stiffness with Esophageo-gastric Variceal Bleeding in Patients with Non-cirrhotic Portal Hypertension.
    Dig Dis Sci. 2025 Sep 2. doi: 10.1007/s10620-025-09356.
    PubMed         Abstract available
    
    
19. RAO AK, Rockey DC
    Impact of Levothyroxine on Progression to and Complications of Cirrhosis in MASH.
    Dig Dis Sci. 2025 Aug 30. doi: 10.1007/s10620-025-09375.
    PubMed         Abstract available
    
    

    
    Endoscopy

20. MIYAZAWA M, Kido H, Nagai K, Hayashi T, et al
    Beware of bile peritonitis caused by kinking of the self-expandable metal stent during endoscopic ultrasound-guided hepaticogastrostomy.
    Endoscopy. 2025;57.
    PubMed        
    
    

    
    Eur Radiol

21. LEWIN M, Aldhaheri R, Beaufrere A, Desterke C, et al
    Imaging features of recently identified low-grade vascular neoplasia of the liver: hepatic small vessel neoplasm and anastomosing hemangioma.
    Eur Radiol. 2025 Sep 4. doi: 10.1007/s00330-025-11915.
    PubMed         Abstract available
    
    

    
    Gut

22. MILARDI G, Franceschini B, Camisaschi C, Puccio S, et al
    Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome.
    Gut. 2025 Aug 31:gutjnl-2025-334861. doi: 10.1136/gutjnl-2025-334861.
    PubMed         Abstract available
    
    

    
    Hepatology

23. LAI JC, Tapper E, Tandon P
    Integrative hepatology: Enhancing overall health to manage liver disease.
    Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001516.
    PubMed         Abstract available
    
    
24. HUANG CH, Ku WT, Wu TH, Lin PT, et al
    Reply to the Letter to the Editor: Revisiting FOXP3 expression and its prognostic implications in hepatocellular carcinoma.
    Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001515.
    PubMed        
    
    
25. ZHANGYUAN G, Yu W, Tian W, Xie J, et al
    RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1-mutated hepatocellular carcinoma.
    Hepatology. 2025 Sep 1. doi: 10.1097/HEP.0000000000001483.
    PubMed         Abstract available
    
    
26. SUN Y, Chen S, Xu X, Piao H, et al
    Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis.
    Hepatology. 2025 Sep 1. doi: 10.1097/HEP.0000000000001504.
    PubMed         Abstract available
    
    
27. ZHANG L, Li H, Zong W, Li B, et al
    Letter to the Editor: Revisiting FOXP3 Expression and its prognostic implications in hepatocellular carcinoma.
    Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001512.
    PubMed        
    
    
28. LIU TH, Yang HC
    Letter to the Editor: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy.
    Hepatology. 2025 Sep 4. doi: 10.1097/HEP.0000000000001459.
    PubMed        
    
    

    
    Int J Cancer

29. SHEN QM, Li ZY, Wang J, Zou YX, et al
    Prediagnostic plasma metabolite concentrations and liver cancer risk: A nested case-control study with long follow-up in the Shanghai Women's Health Study.
    Int J Cancer. 2025;157:1805-1817.
    PubMed         Abstract available
    
    
30. SHEN Q, Shi S, Wang H, Zhang S, et al
    Serum 25-hydroxyvitamin D, vitamin D-related variants, and risk of chronic liver disease.
    Int J Cancer. 2025;157:1781-1794.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

31. KUO CH, El-Omar E, Kao CY, Lin JT, et al
    Compositional and Metabolomic Shifts of the Gut Microbiome in Alcohol-Related Liver Disease.
    J Gastroenterol Hepatol. 2025;40:2176-2189.
    PubMed         Abstract available
    
    
32. CAINES A, Lu M, Wu T, Trudeau S, et al
    Pre-Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis.
    J Gastroenterol Hepatol. 2025 Jun 23. doi: 10.1111/jgh.17035.
    PubMed         Abstract available
    
    
33. ZHANG Y, Jiang L, Jiang Y, Zhu L, et al
    Elevated HSP70 Ameliorates Liver Failure Patients via Its Novel Natural Inhibitor.
    J Gastroenterol Hepatol. 2025;40:2300-2310.
    PubMed         Abstract available
    
    
34. EZHILARASAN D
    Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?
    J Gastroenterol Hepatol. 2025;40:2163-2175.
    PubMed         Abstract available
    
    

    
    J Hepatol

35. ZHOU T
    Optimizing Clinical Adoption of Large Language Models in Hepatology: Toward Terminological Precision, Multilingual Adaptability, and Interpretive Literacy.
    J Hepatol. 2025 Sep 2:S0168-8278(25)02470-5. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
36. DIXON ED, Claudel T, Nardo AD, Riva A, et al
    Erratum to 'Inhibition of ATGL alleviates MASH via impaired PPARa signalling that favours hydrophilic bile acid composition in mice' [J Hepatol 82 (2025) 658-675].
    J Hepatol. 2025 Aug 30:S0168-8278(25)02438-9. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
37. ZHOU H, Ba J, Xiao C, Liu H, et al
    Alcohol activates ATF4/LPLA2-mediated BMP metabolism to enhance HBV-induced hepatocellular carcinogenesis.
    J Hepatol. 2025 Aug 28:S0168-8278(25)02458-4. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
38. ALLAIRE M, Meneghetti AR, Mouri S, Kather JN, et al
    A Role of Non-Selective Beta-Blockers in Preventing Liver Decompensation in Patients with Hepatocellular Carcinoma Undergoing Systemic Therapy.
    J Hepatol. 2025 Sep 3:S0168-8278(25)02469-9. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    

    
    J Pediatr Surg

39. THANH LN, Nguyen HP, Thi HB, Thi Kieu TP, et al
    Outcomes of Allogenic Umbilical Cord Mesenchymal Stem Cell infusion for Liver Cirrhosis due to Biliary Atresia after Kasai Operation.
    J Pediatr Surg. 2025 Sep 2:162624. doi: 10.1016/j.jpedsurg.2025.162624.
    PubMed         Abstract available
    
    

    
    Oncogene

40. WU Z, Duan W, Xiong Y, Liu J, et al
    NeuroD1 drives a KAT2A-FDFT1 signaling axis to promote cholesterol biosynthesis and hepatocellular carcinoma progression via histone H3K27 acetylation.
    Oncogene. 2025 Sep 1. doi: 10.1038/s41388-025-03534.
    PubMed         Abstract available
    
    
41. SUN C, Cai S, Yang J, Du M, et al
    OTUB1 antagonizes TRIM21 to induce deubiquitination of SPHK1 and promote the progression of hepatocellular carcinoma.
    Oncogene. 2025 Aug 30. doi: 10.1038/s41388-025-03556.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

42. XIAO T, Liu Y, Hu K, Guo K, et al
    Drug-induced liver injury prediction based on graph convolutional networks and toxicogenomics.
    PLoS Comput Biol. 2025;21:e1013423.
    PubMed         Abstract available
    
    

    
    PLoS One

43. AHMED RF, Elgamal AM, El-Nashar HAS, Mowaad NA, et al
    Phenolic-rich extracts of Teucrium oliverianum confer protection against thioacetamide-induced liver fibrosis in rats: Insights from metabolomics, biochemical and histopathological analysis.
    PLoS One. 2025;20:e0330595.
    PubMed         Abstract available
    
    
44. ZHU J, Chen Y, Han Y, Li J, et al
    Mechanism of Huanglian Wendan Decoction in ameliorating non-alcoholic fatty liver disease via modulating gut microbiota-mediated metabolic reprogramming and activating the LKB1/AMPK pathway.
    PLoS One. 2025;20:e0331303.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

45. ROUZBAHANI M
    Precision Risk Stratification in Hepatocellular Carcinoma: Clinical Relevance of CatBoost-based Prediction Following TACE.
    Radiol Imaging Cancer. 2025;7:e250386.
    PubMed        
    
    
46. WEI R, Liu Z, Ju L, Zuo M, et al
    Using Machine Learning to Predict Advanced-Stage Progression of Intermediate-Stage Hepatocellular Carcinoma after Transarterial Chemoembolization.
    Radiol Imaging Cancer. 2025;7:e250034.
    PubMed         Abstract available
    
    

    
    Transplant Proc

47. AGALAR C, Egeli T, Ozbilgin M, Sakaoglu B, et al
    Pathologic Complete Response as a Prognostic Indicator in Bridging Therapy: A 25-Year Retrospective Study on Hepatocellular Carcinoma and Liver Transplantation Outcomes.
    Transplant Proc. 2025 Aug 30:S0041-1345(25)00375.
    PubMed         Abstract available
    
    
48. AGALAR C, Egeli T, Aysal A, Ozbilgin M, et al
    HALP Score Predicts Early Post-Transplant Outcomes: A 25-Year Retrospective Study on Hepatocellular Carcinoma and Liver Transplantation Outcomes.
    Transplant Proc. 2025 Aug 30:S0041-1345(25)00372.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.